Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application nitrofurantoin capsules USP (Monohydrate/Macrocrystals) 100mg. Aurobindo Pharma’s nitrofurantoin capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Macrobid Capsules manufactured by Almatica Pharma.
Nitrofurantoin capsulesare indicated for for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.
Nitrofurantoin capsules has an estimated market size of US $57 Million for the twelve months ending January 2023, as per IQVIA.
